- agreements signed with UK-based MedTrade Products Limited
and U.S.-based Mueller Medical International LLC -
BELLEVILLE, ON, Dec. 21, 2011 /CNW/ - Bioniche Life Sciences Inc. (TSX:
BNC) (ASX: BNC), a research-based, technology-driven Canadian
biopharmaceutical company, today announced that it has entered into two
distribution agreements to expand its product offerings in North
MedTrade Distribution Agreement
The first agreement is with MedTrade Products Limited ("MedTrade"), a
UK-based company. The agreement provides a number of equine and
companion animal health products based on MedTrade's CeloxTM technology for exclusive distribution by Bioniche in Canada.
The CeloxTM technology uses chitosan, a natural polysaccharide, as a medical device
in the animal health industry. The CeloxTM product line includes gauzes and granules that are utilized in wound
healing. When mixed with blood, CeloxTM forms a gel-like clot in less than one minute, independent of the
body's normal clotting processes. Unlike some other clotting agents,
CeloxTM is non-exothermic so will not burn the patient or caregiver. In human
medicine, CeloxTM has been used by military medics and emergency services workers for a
number of years and has been proven to stop even potentially lethal
Mueller Medical Distribution Agreement
The second agreement is with Mueller Medical International LLC ("Mueller
Medical"), a U.S.-based company. The agreement provides an equine
product - Equine Gastrafate® - for exclusive distribution in Canada and the U.S. by Bioniche.
Equine Gastrafate® is a patented saccharide composition that is used to expedite
management of gastrointestinal syndromes characterized by nausea,
vomiting, diarrhea, colic and mucosal erosions. This product is often
used by equine veterinarians who suspect ulcer colic in horses.
"Equine Gastrafate® has been field tested in all breeds of horses over a four-year period
by 32 equine veterinarians in 19 U.S. states and has proven to be an
effective treatment," said Mr. Andrew Grant, President of Bioniche
Animal Health (global). "The CeloxTM product line is a good fit with our existing North American product
offering for companion animal and equine wound healing, alongside such
products as PERIDAN® Concentrate, to prevent adhesions in horses following abdominal surgery and Derma-GeL®, a topical isotonic hydrogel that promotes wound healing in horses and
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a research-based, technology-driven
Canadian biopharmaceutical company focused on the discovery,
development, manufacturing, and marketing of proprietary and innovative
products for human and animal health markets worldwide. The
fully-integrated company employs more than 200 skilled personnel and
has three operating divisions: Human Health, Animal Health, and Food
Safety. The Company's primary goal is to develop and commercialize
products that advance human or animal health and increase shareholder
Bioniche Life Sciences Inc. has been named one of the Top 50 Best Small
and Medium-Sized Employers in Canada for 2010. For more information,
please visit www.Bioniche.com.
Except for historical information, this news release may contain
forward-looking statements that reflect the Company's current
expectation regarding future events. These forward-looking statements
involve risk and uncertainties, which may cause, but are not limited
to, changing market conditions, the successful and timely completion of
clinical studies, the establishment of corporate alliances, the impact
of competitive products and pricing, new product development,
uncertainties related to the regulatory approval process, and other
risks detailed from time to time in the Company's ongoing quarterly and
SOURCE Bioniche Life Sciences Inc.
For further information:
Jennifer Shea, Vice-President, Communications, Investor & Government Relations
Bioniche Life Sciences Inc.
Telephone: (613) 966-8058; from Australia: 0011 1 613-966-8058
Cell: (613) 391-2097; from Australia: 0011 1 613-391-2097